Cancer Vaccines Market Expected to Experience Accelerated Growth and Market Evolution by 2034 - DelveInsight

DelveInsight's "Cancer Vaccines Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Cancer Vaccines, historical and forecasted epidemiology as well as the Cancer Vaccines market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Cancer Vaccines market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Cancer Vaccines Market Forecast
https://www.delveinsight.com/sample-request/cancer-vaccines-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Cancer Vaccines Market Report:
• The Cancer Vaccines market size is anticipated to grow with a significant CAGR during the study period (2020-2034).
• In May 2026, Guardant Health announced that the U.S. FDA has approved its Guardant360® CDx liquid biopsy test as a companion diagnostic for VEPPANU (vepdegestrant). Developed collaboratively by Arvinas and Pfizer, VEPPANU is indicated for adults with estrogen receptor-positive (ER+), HER2-negative (HER2-), ESR1-mutated advanced or metastatic breast cancer, identified through an FDA-authorized diagnostic test, whose disease has progressed after receiving at least one prior endocrine therapy.
• In May 2026, The FDA has granted approval to vepdegestrant (Veppanu) for the treatment of patients with estrogen receptor (ER)-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer, as identified through an FDA-authorized diagnostic test, according to an official agency announcement. In addition, the FDA approved the Guardant360 CDx companion diagnostic to aid in detecting ESR1 mutations in eligible patients. The approval decision was supported by findings from the Phase 3 VERITAC-2 trial (NCT05654623), which evaluated vepdegestrant as a monotherapy for patients with advanced metastatic breast cancer.
• In March 2025, Everest Medicines administered the first dose of EVM16, its personalized mRNA cancer vaccine, to a participant in the first-in-human (FIH) trial, EVM16CX01.
• In February 2025, In a Phase I investigator-led trial, all nine patients who received a personalized kidney cancer vaccine developed anti-cancer immune responses after undergoing tumor removal surgery. Researchers at the Dana-Farber Cancer Institute in the U.S. administered the NeoVax personalized cancer vaccine to patients with stage III or IV clear cell renal cell carcinoma (ccRCC) following their surgeries.
• In August 2024, BioNTech launched global clinical trials for BNT116, an mRNA vaccine being developed as a potential treatment for non-small cell lung cancer (NSCLC). The vaccine utilizes the same mRNA technology that played a crucial role in the development of Covid-19 vaccines.
• In February 2024, A cancer vaccine trial initiated by Moderna commenced in the UK, with researchers optimistic about ushering in a new era of treatments.
• In 2023, the estimated number of incident cases of non-small cell lung cancer (NSCLC) in the US was approximately 200,000.
• Uveal melanoma impacts approximately 500 to 600 individuals annually in the UK.
• The cancer vaccines market features a robust and expanding pipeline with candidates such as IO102-IO103 (IO Biotech), CAN-2409 (Candel Therapeutics), mRNA-4157 (V940) combined with KEYTRUDA (Merck and Moderna), PDClung01 (PDCline Pharma/LG Chem), and LB-LR1109 (LG Chem and AVEO Oncology). These vaccines target a variety of cancers, including non-small cell lung cancer (NSCLC), colorectal cancer, glioblastoma, melanoma, breast cancer, and more.
• Key Cancer Vaccines Companies: Dendreon Pharma, Candel Therapeutics, GlaxoSmithKline, Merck, Aduro Biotech, Astrazeneca Plc, Dendreon, Astellas Pharma Inc, Sanofi, , Sanpower Group and CSL Ltd., Northwest Biotherapeutics, IO Biotech, Immunomic Therapeutics, Evaxion Biotech, Candel Therapeutics, Aston Sci, Evaxion Biotech, and others
• Key Cancer Vaccines Therapies: DCVax-L, IO102-IO103, ITI-1000, EVX-01, CAN-2409, AST-301, EVX-02, and others
• Several vaccine constructions have been tested for anticancer therapy. In each case, these vaccines are designed to present tumor-associated peptides integrated with MHC molecules to cognate receptors on B or T lymphocytes and stimulate their activation, maturation, and proliferation
• The Cancer Vaccines market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Cancer Vaccines pipeline products will significantly revolutionize the Cancer Vaccines market dynamics.

Cancer Vaccines Overview
Cancer vaccines are a type of immunotherapy designed to stimulate the body's immune system to recognize and attack cancer cells. Unlike traditional vaccines, which prevent infectious diseases by priming the immune system to recognize and fight off specific pathogens (such as viruses or bacteria), cancer vaccines are used to treat existing cancer or to prevent cancer recurrence.

Get a Free sample for the Cancer Vaccines Market Report:
https://www.delveinsight.com/report-store/cancer-vaccines-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Cancer Vaccines Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Cancer Vaccines Epidemiology Segmentation:
The Cancer Vaccines market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalence of Cancer Vaccines
• Prevalent Cases of Cancer Vaccines by severity
• Gender-specific Prevalence of Cancer Vaccines
• Diagnosed Cases of Episodic and Chronic Cancer Vaccines

Download the report to understand which factors are driving Cancer Vaccines epidemiology trends @ Cancer Vaccines Epidemiology Forecast
https://www.delveinsight.com/sample-request/cancer-vaccines-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Cancer Vaccines Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Cancer Vaccines market or expected to get launched during the study period. The analysis covers Cancer Vaccines market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Cancer Vaccines Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Cancer Vaccines Therapies and Key Companies
• PROVENGE (sipuleucel-T): Dendreon Pharmaceuticals
• CAN-2409: Candel Therapeutics
• LB-LR1109: LG Chem and AVEO Oncology
• DCVax-L: Northwest Biotherapeutics
• IO102-IO103: IO Biotech
• ITI-1000: Immunomic Therapeutics
• EVX-01: Evaxion Biotech
• CAN-2409: Candel Therapeutics
• AST-301: Aston Sci
• EVX-02: Evaxion Biotech

Discover more about therapies set to grab major Cancer Vaccines market share @ Cancer Vaccines Treatment Market
https://www.delveinsight.com/sample-request/cancer-vaccines-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Cancer Vaccines Market Strengths
• Advancements in computational and bioinformatics platforms and several other R&D practices enable the development of cancer neoantigen vaccination strategies
• Neoantigen-based Personalized Cancer Therapeutic Vaccines like Vigil and Tedopi along with few others can stimulate immune responses to checkpoint inhibitors even in patients that have previously failed conventional treatment regimes, thereby, addressing potential unmet needs of the market

Cancer Vaccines Market Opportunities
• Rising incidence of cancer will provide a larger window of opportunity for these novel vaccines
• Recurrence is very common in cancers even after proper treatment. This opens up new window for Neoantigen-based Personalized Cancer Therapeutic Vaccines to dominate the treatment regime

Scope of the Cancer Vaccines Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Cancer Vaccines Companies: Dendreon Pharma, Candel Therapeutics, GlaxoSmithKline, Merck, Aduro Biotech, Astrazeneca Plc, Dendreon, Astellas Pharma Inc, Sanofi, Sanpower Group and CSL Ltd., Northwest Biotherapeutics, IO Biotech, Immunomic Therapeutics, Evaxion Biotech, Candel Therapeutics, Aston Sci, Evaxion Biotech, and others
• Key Cancer Vaccines Therapies: DCVax-L, IO102-IO103, ITI-1000, EVX-01, CAN-2409, AST-301, EVX-02, and others
• Cancer Vaccines Therapeutic Assessment: Cancer Vaccines current marketed and Cancer Vaccines emerging therapies
• Cancer Vaccines Market Dynamics: Cancer Vaccines market drivers and Cancer Vaccines market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Cancer Vaccines Unmet Needs, KOL's views, Analyst's views, Cancer Vaccines Market Access and Reimbursement

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.